134 results on '"Ullmann, Andrew J"'
Search Results
2. Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154+Aspergillus fumigatus specific T-cell quantification
3. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
4. Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure
5. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
6. Clinical-scale isolation of the total Aspergillus fumigatus–reactive T–helper cell repertoire for adoptive transfer
7. Intra‐ and inter‐individual variability of Aspergillus fumigatus reactive T‐cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment
8. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
9. Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation
10. Numbers Needed to Treat with Posaconazole Prophylaxis to Prevent Invasive Fungal Infection and Death
11. Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
12. Estimated burden of fungal infections in Germany
13. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry
14. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
15. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species
16. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting
17. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole
18. Preface
19. Comparison of 2 studies of treatment of invasive aspergillosis
20. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
21. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial)
22. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
23. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and ≤106/kg T cells may have an adverse effect on transplant-related mortality
24. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections
25. Opportunistische Infektionen nach Therapie mit monoklonalen Antikörpern
26. Impfungen bei immunsupprimierten Erwachsenen mit hämato-onkologischer Erkrankung
27. Aktuelle Entwicklungen in der Diagnostik und Therapie von systemischen Pilzinfektionen bei Krebspatienten
28. Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with Febrile Neutropenia
29. Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation
30. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
31. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
32. Economic Evaluation of Voriconazole versus Conventional Amphotericin B in the Treatment of Invasive Aspergillosis in Germany
33. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
34. Safety of micafungin in prospective and retrospective clinical trials
35. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
36. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
37. Posaconazole concentrations in the central nervous system
38. Nephrotoxicity in the setting of invasive fungal diseases
39. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis
40. Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease
41. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats
42. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
43. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia
44. Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies
45. Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study
46. Treatment of fungal infections in hematology and oncology
47. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies
48. Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells.
49. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
50. Susceptibility of A. fumigatus‐specific T‐cell assays to pre‐analytic blood storage and PBMC cryopreservation greatly depends on readout platform and analytes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.